NIH's National Library of Medicine Reopened the Clinical Informatics R01 (PAR-26-042) Through 2029, with $250K Direct Costs Per Year and a Narrow Responsiveness Window. The Next Deadline Is October 5 — and the Disqualification Criteria Are Where Most Applications Will Fail.

The National Library of Medicine, the smallest of NIH's twenty-seven institutes and centers, just reopened its long-standing clinical informatics R01 line under a new five-year notice: PAR-26-042, Research Grants in Clinical Informatics (R01 Clinical Trial Optional). The notice posted in late May, accepts applications through standard NIH cycles, and remains active through March 6, 2029. Direct costs are capped at $250,000 per year for projects of up to five years, putting the all-in award envelope at roughly $1.5 million in total costs over the full project period. The first standard receipt date under the new notice was June 5, 2026. The next two receipt dates are October 5, 2026, and February 5, 2027.

For institutions that have been watching NIH absorb a sequence of disruptive policy and budget actions over the last twelve months — the SBIR/STTR lapse and reauthorization (deep dive here), the OMB rewrite of 2 CFR 200, the contestation of indirect cost rates, and the layered legal challenges to discretionary award terminations — the reopening of a stable, well-scoped clinical informatics line is more than a routine notice refresh. It is one of the few NIH funding streams in 2026 that operates on the traditional contours of biomedical extramural research: standard receipt dates, defined direct cost ceiling, clinical-trial-optional design, peer review through study sections, and a multi-year notice horizon that lets investigators plan resubmissions. The funding envelope is modest by NIH standards. The strategic value of the predictability is not.

This piece works through what PAR-26-042 funds, what it explicitly will not fund, why the NLM responsiveness criteria are the most important part of the notice, how the funding fits into the broader NIH biomedical informatics landscape, and how investigators should sequence their applications across the October 2026, February 2027, and subsequent receipt dates.

What PAR-26-042 Funds

The notice supports investigator-initiated research in clinical informatics — defined by NLM as the application of informatics methods to patient care, health services, and population health within clinical contexts. The supported research includes the development and rigorous evaluation of new informatics methods, the application of methods to specific clinical problems, the study of how informatics interventions change clinical workflows and outcomes, and the development of new computational approaches to clinical data that produce generalizable knowledge rather than site-specific tools.

The clinical-trial-optional design is important. Investigators may propose clinical trials when needed to evaluate an informatics intervention, but the trial cannot be the primary aim. The intent is to fund informatics research that may include controlled evaluation as a method, not to fund clinical trials that happen to use informatics tools.

The $250,000 direct-cost cap is the same ceiling NLM has used for its clinical informatics R01 line for several previous notice cycles. The number sits below the general NIH R01 modular budget ceiling and represents a deliberate program design choice: NLM is funding many smaller projects rather than a few large ones, on the theory that clinical informatics methodology is best advanced through a portfolio of focused studies rather than through large infrastructure-heavy efforts.

The notice supports the standard R01 mechanism, which means the budget can include personnel, computing infrastructure, data acquisition, software licensing, modest equipment, and indirect costs at the institution's negotiated rate. Multi-PI applications are permitted under standard NIH rules. Foreign collaboration is permitted but is subject to the heightened scrutiny that all NIH applications now face under the foreign-influence and foreign-collaboration provisions in the new OMB framework.

What PAR-26-042 Will Not Fund

The most operationally important section of the notice is the non-responsive criteria. NLM has used responsiveness language in past clinical informatics notices, but the PAR-26-042 version is more explicit. Three categories of project are flagged as non-responsive:

The first is projects that propose incremental improvements to existing informatics tools. NLM is signaling that it is not interested in funding the next iteration of an already-published natural language processing pipeline, an additional feature on an existing decision support system, or a small refinement to a previously demonstrated method. The notice wants methodological advances — new approaches, new combinations, new validations on substantively different data — not engineering increments on prior work. Applications that read as "v2 of the published tool" will be triaged at scientific review.

The second is projects primarily focused on social determinants of health. NLM's reasoning is that SDOH research has its own funding lines at other NIH institutes — the All of Us Research Program, the NIMHD portfolio, the NHLBI population sciences program, and several R01 PARs at other ICs. The NLM clinical informatics line is for informatics-methodological work. Projects that use informatics methods incidentally to study an SDOH question will be redirected. The way around the criterion, for investigators whose work touches SDOH, is to position the application as developing informatics methods that have SDOH data as a test case, rather than as using informatics to answer an SDOH question. The distinction is fine but real and will be applied at review.

The third is projects primarily focused on ethical, legal, and social issues. ELSI research has its own dedicated funding lines, most notably at NHGRI and at the NIH Office of the Director. The NLM clinical informatics line is for clinical informatics methodology, not for the policy or ethical analysis of informatics deployments. Applications that propose qualitative or normative analyses of how clinical informatics affects clinicians, patients, or institutions will be considered non-responsive even if methodologically rigorous.

These three exclusions are not new to NIH program management but they are unusually explicit in this notice. The likely reason is that prior clinical informatics R01 cycles attracted a substantial volume of borderline applications that NLM staff judged off-target but that reviewers, lacking the explicit guidance, scored on the merits. Making the criteria visible upfront moves the triage decision from the review meeting to the investigator's pre-submission planning.

Why the Notice Matters in the Current NIH Environment

Three contextual facts make PAR-26-042 unusually important relative to its modest dollar size.

The first is the SBIR/STTR rollout. NIH SBIR/STTR programs only reopened in May 2026 after the program lapse, and the small-business funding stream is still working through its post-reauthorization rhythm. Investigators in academic departments who were planning to support graduate students or postdocs on industry collaborations through SBIR mechanisms are looking for academic-side replacement funding. The NLM clinical informatics R01 is one of the most available academic mechanisms for informatics-focused trainees, particularly because the modular budget structure can support a graduate student plus a postdoc plus PI time within the $250K cap without elaborate cost-sharing arrangements.

The second is the OMB Uniform Grants Regulation rewrite (Granted News brief here). The proposed rule would insert senior political appointees into the pre-issuance review of discretionary awards, expand agency termination authority, and codify new compliance requirements including E-Verify enrollment and additional foreign-collaboration scrutiny. The rule is in comment period through July 13, 2026, with a proposed effective date of October 1. R01 awards, while technically discretionary, sit within the most institutionally protected portion of the NIH funding pipeline and would likely receive less politically driven termination scrutiny than competitive grants from other agencies. The funding line is therefore among the more stable academic biomedical funding streams in an environment where stability has become rare.

The third is the broader politics of NIH funding. NIH's FY2026 appropriations process preserved overall agency funding but came with substantial directive language about institute-level priorities. NLM, as a smaller institute with a defined methodological mandate and a long track record of bipartisan support, has been less exposed to the appropriations debate than larger institutes whose program portfolios are politically contested. Investigators who can credibly position their work within the NLM methodological frame have one of the lower-risk paths through the FY26 funding environment.

How to Sequence Applications Across the Notice Period

PAR-26-042 expires March 6, 2029, which means the notice will support nine standard receipt dates across its lifetime: three in 2026 (the June date already passed), three in 2027, three in 2028, and the final cycle on February 5, 2029. Investigators with multi-cycle plans should think about which receipt date is best for a given application.

The October 5, 2026 receipt date is the most strategically valuable submission window for new investigators. The summer-fall submission cycle reviews into the spring council meeting and decisions in the May-June 2027 window, which means awards starting in the September 2027 funding cycle. The eighteen-month time-to-money is the standard NIH cadence; what matters is that October 2026 is the first full submission with the new notice's responsiveness criteria explicit, which means the review panel will be operating with a clean responsiveness frame and is likely to be more receptive than later cycles when the visible non-responsive applications have already been triaged out of the queue.

The February 5, 2027 receipt date is the right window for investigators who have already submitted a related application under a different mechanism and received reviewer feedback. The four-month gap between October and February permits a substantial revision cycle, and the February submission gives sufficient time before the standard NIH summer council meeting.

The June 5, 2027 receipt date is the right window for resubmissions of October 2026 applications that were not funded but received reviewable scores. The receipt date sits well after the spring council meeting and gives investigators time to respond systematically to the summary statement. NLM has historically given resubmissions a fair second look in the clinical informatics line, particularly for investigators whose responsiveness profile improved between submissions.

Investigators in years 2028 and 2029 should monitor for an early notice expiration or reissuance announcement. NLM has a pattern of refreshing its R01 PARs every two to three years even when a multi-year expiration is published, and the responsiveness criteria are the most likely element to be revised. Late-cycle applications should be drafted with the current criteria but with attention to whether NLM signals any methodological priority shifts in conference talks, NIH Director's blog posts, or institute-level guide notices.

What a Competitive Application Looks Like

The applications that win NLM clinical informatics R01s in 2026 will share three features.

The first is a clear methodological aim that is not solvable with current tools. The notice is for new informatics methods or substantively new applications of existing methods to a clinical problem. Applications that propose to "implement and evaluate" a method that has already been demonstrated will be marked incremental. Applications that propose a new method, validate it against a defined comparator, and quantify its effect on a clinically meaningful endpoint will be marked methodologically responsive.

The second is a defined clinical context with a credible institutional partner. NLM is not interested in pure methodology developed against synthetic data or against a clinical dataset that the PI cannot demonstrate continued access to. The strongest applications come from PIs who have a documented data use agreement, an institutional EHR system with a defined informatics partnership office, and a clinical co-investigator whose patient-care role gives the work face validity. This is also where multi-PI applications gain leverage: an informatics-methodology PI paired with a clinician-investigator PI is a stronger application than either alone.

The third is an evaluation plan that produces generalizable knowledge. NLM has historically preferred applications that frame their evaluation in terms transferable to other institutions and clinical contexts, rather than evaluations that demonstrate effect at a single site. The framing matters at scientific review: reviewers will mark down applications whose generalizability claims are not supported by the design.

For investigators who can clear the responsiveness bar and write to these three features, PAR-26-042 is one of the highest-confidence funding paths in NIH's 2026 portfolio. The dollars are modest. The predictability is the asset.